Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?
Hosp Pharm
; 49(8): 697-701, 2014 Sep.
Article
en En
| MEDLINE
| ID: mdl-25477593
Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is firmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs for lowering serum glucose, none to date have been shown to substantially reduce CV risk and some have been associated with adverse effects. Recent trials have examined the CV effects of the dipeptidyl peptidase 4 (DPP-4) inhibitors or "gliptins."
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Hosp Pharm
Año:
2014
Tipo del documento:
Article
Pais de publicación:
Estados Unidos